Takimoto CH - Search Results

1

Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.

Mita M, Mita A, Sarantopoulos J, Takimoto CH, Rowinsky EK, Romero O, Angiuli P, Allievi C, Eisenfeld A, Verschraegen CF. Mita M, et al. Among authors: takimoto ch. Cancer Chemother Pharmacol. 2009 Jul;64(2):287-95. doi: 10.1007/s00280-008-0869-5. Epub 2008 Nov 25. Cancer Chemother Pharmacol. 2009. PMID: 19034451 Clinical Trial.

2

A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.

Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, Mita AC, de Bono JS, Tolcher AW, Hammond LA, Simmons P, Berg K, Takimoto C, Patnaik A. Mita MM, et al. Cancer Chemother Pharmacol. 2007 Feb;59(2):165-74. doi: 10.1007/s00280-006-0255-0. Epub 2006 May 31. Cancer Chemother Pharmacol. 2007. PMID: 16736151 Clinical Trial.

3

Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.

Mita M, Kelly KR, Mita A, Ricart AD, Romero O, Tolcher A, Hook L, Okereke C, Krivelevich I, Rossignol DP, Giles FJ, Rowinsky EK, Takimoto C. Mita M, et al. Clin Cancer Res. 2011 Jan 1;17(1):193-200. doi: 10.1158/1078-0432.CCR-10-0010. Clin Cancer Res. 2011. PMID: 21208908 Clinical Trial.

4

Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.

Saif MW, Sarantopoulos J, Patnaik A, Tolcher AW, Takimoto C, Beeram M. Saif MW, et al. Cancer Chemother Pharmacol. 2011 Dec;68(6):1565-73. doi: 10.1007/s00280-011-1639-3. Epub 2011 May 6. Cancer Chemother Pharmacol. 2011. PMID: 21547572 Clinical Trial.

5

Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.

Lin CC, Calvo E, Papadopoulos KP, Patnaik A, Sarantopoulos J, Mita AC, Preston GG, Mita MM, Rodon J, Mays T, Yeh IT, O'Rourke P, Takimoto CH, Dancey JE, Chen H, Tolcher AW. Lin CC, et al. Among authors: takimoto ch. Cancer Chemother Pharmacol. 2009 May;63(6):1065-71. doi: 10.1007/s00280-008-0811-x. Epub 2008 Sep 16. Cancer Chemother Pharmacol. 2009. PMID: 18795291 Clinical Trial.

6

Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.

Lin CC, Beeram M, Rowinsky EK, Takimoto CH, Ng CM, Geyer CE Jr, Denis LJ, De Bono JS, Hao D, Tolcher AW, Rha SY, Jolivet J, Patnaik A. Lin CC, et al. Among authors: takimoto ch. Cancer Chemother Pharmacol. 2009 Dec;65(1):167-75. doi: 10.1007/s00280-009-1020-y. Epub 2009 May 16. Cancer Chemother Pharmacol. 2009. PMID: 19449006 Clinical Trial.

7

A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).

Rodon J, Jacobs CD, Chu Q, Rowinsky EK, Lopez-Anaya A, Takimoto CH, Wakelee HA. Rodon J, et al. Among authors: takimoto ch. Cancer Chemother Pharmacol. 2012 Mar;69(3):825-34. doi: 10.1007/s00280-011-1770-1. Epub 2011 Nov 6. Cancer Chemother Pharmacol. 2012. PMID: 22057853 Clinical Trial.

8

Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial.

Tsimberidou AM, Takimoto CH, Moulder S, Uehara C, Mita M, Mita A, Urban P, Tan E, Wang Y, Vining D, Kurzrock R. Tsimberidou AM, et al. Among authors: takimoto ch. Mol Cancer Ther. 2011 Jan;10(1):209-17. doi: 10.1158/1535-7163.MCT-10-0774. Mol Cancer Ther. 2011. PMID: 21220503 Clinical Trial.

9

A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.

Schwartz GH, Jones CB, Garrison M, Patnaik A, Takimoto C, McCreery H, Skinner M, Tolcher AW, Rowinsky EK. Schwartz GH, et al. Invest New Drugs. 2004 Nov;22(4):437-48. doi: 10.1023/B:DRUG.0000036686.86700.a9. Invest New Drugs. 2004. PMID: 15292714 Clinical Trial.

10

A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.

Syed S, Takimoto C, Hidalgo M, Rizzo J, Kuhn JG, Hammond LA, Schwartz G, Tolcher A, Patnaik A, Eckhardt SG, Rowinsky EK. Syed S, et al. Clin Cancer Res. 2004 Oct 1;10(19):6512-21. doi: 10.1158/1078-0432.CCR-04-0804. Clin Cancer Res. 2004. PMID: 15475438 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters